All News
How do you manage enthesitis?
Enthesitis can be a challenge for clinicians to identify, evaluate, and manage in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). It affects 27-35% of PsA patients and 36% of axSpA patients. Dr.
Read Article
In 551 juvenile myositis pts, 36% had myositis assoc Abs (MAA); 13% had >1 MAA. MAA+ pts had more overlap dz (18 vs 6%, p<.001) & assoc w/ Raynauds (OR 2.44), ILD (OR 3.43), chronic Dz (OR 1.72), mortality (OR 3.76). # MAAs was assoc w/ mortality (OR 1.83) https://t.co/BXhasmel3Z
Dr. John Cush RheumNow ( View Tweet)
Study of 43 SSc patients w/ gangrene shows Smoking Hx ; positive-ACA, ANCA, APL Abs & high ESR were independent risk factors for digital gangrenes in SSc. Vasculitis and macrovascular disease may contribute to the progression of digital gangrene https://t.co/3DY2Hx19s0 https://t.co/BfXANmckwF
Dr. John Cush RheumNow ( View Tweet)
Tonix is developing a drug, TNX-102 SL, that targets poor sleep quality for fibromyalgia. Phase 3 trial in FM (457 pts) showed TNX-102 SL was better (vs PBO) & improved sleep quality (p=0.0000001 & improved daily pain (p=0.00005) https://t.co/QUNdWyNj2l https://t.co/CzD5TEcgTk
Dr. John Cush RheumNow ( View Tweet)
Taiwan National Health claims data looked at drugs & gout flares. Signif increase flares were seen w/ ASA, thiazides, loop diuretics, ethambutol, pyrazinamide (1.15-3.35) & metformin (SR=1.14). Lower risk w/ fenofibrate (SR=0.60) & losartan (0.92) https://t.co/eBiiM83ei0 https://t.co/296XAbxwkc
Dr. John Cush RheumNow ( View Tweet)
Retro study of 1,169 pts (age 66 yrs) receiving intra-articular steroids & changes on A1C. A1C increases were assoc w/ higher baseline A1C (OR 1.84) for A1C 7–8 (vs <7%) or A1C >8% (OR 4.8 ). YET most patients do not experience increase A1C after IACS https://t.co/eWyO0nHgdy https://t.co/4UQRbrUyz7
Dr. John Cush RheumNow ( View Tweet)
Brazilian registry of 1316 RA pts on bDMARDs or JAKi-Added use of antimalarials reduced SAEs & total AEs, & incr survival. 19% were on HCQ, & had signif less SAEs (mIRR: 0.49); AEs (0.68); serious infections (0.53); hepatic AEs (0.21); & mortality (P=.003) https://t.co/bAZ8m3OBo2 https://t.co/SlneyfbJIh
Dr. John Cush RheumNow ( View Tweet)
Could Weight-Loss Drug Improve Hip Replacement Outcomes?
The antidiabetic/weight-loss drug semaglutide either does or does not help patients undergoing THA avoid complications and other poor outcomes, according to 2 retrospective studies presented here.
https://t.co/bB2E4T2aiI https://t.co/EWVcQ01GuL
Dr. John Cush RheumNow ( View Tweet)
What are the Early Stages of Lupus?
Incomplete lupus? Undifferentiated connective tissue disease? Pre-clinical autoimmune disease?
https://t.co/kl1ePmQ5zf https://t.co/5MgIt4QyJV
Dr. John Cush RheumNow ( View Tweet)
5 yr prospective observational study of 246 pts w/ nonradiographic Axial Spa shows that 16% of nr-axSpA progressed to r-axSpA w/in 5 yrs. SI progression more likely w/ Male sex (HR 3.16), imaging sacroiliitis (HR 6.6), & good NSAID response (HR 4.6) https://t.co/kXXhYaNqRz https://t.co/OD0rowut9k
Dr. John Cush RheumNow ( View Tweet)
But MTX does not prevent CV events in cardiac rush pts (without rheum dz). Results of the CIRT trial. #RWCS24 https://t.co/45aLt6qf27
Dr. John Cush RheumNow ( View Tweet)
DMARDs, MTX & TNFi can lower CV risk in RA pts. #RWCS24 https://t.co/Un457RYL8R
Dr. John Cush RheumNow ( View Tweet)
Marketing analysis of systemic sclerosis prevalence estimates, from 7 major countries, ~150,000 SSc pts in 2022 (47% from US; 20% Japan; 10% UK). https://t.co/0zJFdq05Xd https://t.co/HWM3LNtHbS
Dr. John Cush RheumNow ( View Tweet)
Board question/clinical pearl alert: Hairy Kidney Sign is an important indicator of Erdheim-Chester. Dr. @anisha_dua #RWCS24 @RheumNow @RWCSmtg - abnormal histiocytes now classified as malignancy - bone pain common presenting complaint - can see aorta, pleura, pericardium… https://t.co/XO5GXSNJZk https://t.co/gBn8Hii7F0
Dr. Rachel Tate uptoTate ( View Tweet)
Beautiful graphic from Lyu X describing CAR-T development/manufacturing. Dr. @susanshenoi #RWCS24 @RheumNow @RWCSmtg https://t.co/yujfZeBaW7
Dr. Rachel Tate uptoTate ( View Tweet)
Hot off the press! Case report inspired by Dr. George Martin. Topical ruxolitinib efficacy in cutaneous DM. Dr. @susanshenoi #RWCS24 @RWCSmtg @RheumNow https://t.co/uyJdvgJ0ue
Dr. Rachel Tate uptoTate ( View Tweet)
Ixekizumab Safety from 25 RCTs (17 PsO, 4 PsA, 4 axSpA) w/ 9225 pts (22371 PYs use). Long-term safety c/w earlier reports/PI. SAEs in 1204 (13%); 45 deaths); ISRs 5.9-11.6/100PYs; IBD ≤ 0.8/100PY; depression, CVA, Cancer : ≤ 1.6/100PY https://t.co/p7N6ZMVvqh https://t.co/22WYkevhaf
Dr. John Cush RheumNow ( View Tweet)
Gut microbiota in SpA. Interesting data from @RWCSmtg @JointMD regarding the gut microbiome, both shared and distinct, in SpA, non-infectious AAU and Crohn's. #RWCS24 @RheumNow https://t.co/tHGl01WJ1o
Dr. Rachel Tate uptoTate ( View Tweet)
"It's hard not to be jealous of the dermatologists." @JointMD discussing the results of JNJ 77242113, po IL-23R, the Frontier 1 trial. #RWCS24 @RWCSmtg @RheumNow https://t.co/1zQ6bu5TM2
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Current PsA treatment options. A review with @RWCSmtg @JointMD #RWCS24 @RheumNow https://t.co/9I0TfyILvQ
Dr. Rachel Tate uptoTate ( View Tweet)